Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Lexiva (Fosamprenavir, Telzir)

The Basics | News & Research

Show Archived (Historical) Articles

Brand Name:	Lexiva
Generic Name:	Fosamprenavir calcium, FPV
Adult Single Dose:	Therapy-naive patients: two 700-mg tablets (twice a day) without ritonavir OR two 700-mg tablets plus two 100-mg ritonavir capsules (once a day) OR one 700-mg tablet (twice a day) plus one 100-mg ritonavir capsule (twice a day) Protease inhibitor- experienced patients: one 700-mg tablet (twice a day) plus one 100-mg ritonavir capsule (twice a day) -- once a day administration of fosamprenavir plus ritonavir is not recommended in protease inhibitor-experienced patients) Adjustment of ritonavir dose only when fosamprenavir plus ritonavir are administered once a day with efavirenz: two 700-mg tablets (once a day) plus three 100-mg ritonavir capsules (once a day)
Food & Liquid Restrictions:	None
Drug Class:	PI

The Basics

An Overview of Lexiva (Fosamprenavir, Telzir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Lexiva (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Fosamprenavir (Telzir, Lexiva) (November 13, 2008)
To read PDF, click here
From AIDS InfoNet
Patient Information About Lexiva (Fosamprenavir, Telzir) (PDF) (October 2008)
From GlaxoSmithKline
Labeling Update for Lexiva (Fosamprenavir) (December 21, 2007)
From U.S. Food and Drug Administration
Lexiva (Fosamprenavir) (November 8, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
Fosamprenavir (908, Lexiva, Telzir) (August 15, 2006)
From AIDS Treatment Data Network
Lexiva (Fosamprenavir) (May 2005)
To read PDF, click here
From The Center for AIDS
Drug Interactions: Fosamprenavir (August 2004)
From Project Inform
Fosamprenavir: A New Protease Inhibitor Option (February 2004)
An interview with Jeffrey Nadler, principal investigator of the pivotal NEAT study.
To read PDF, click here
In IAPAC Monthly, from International Association of Physicians in AIDS Care

News & Research

Clinical Trials Using Fosamprenavir (Lexiva) (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Literature Citations for Fosamprenavir (Lexiva) (Regularly Updated)
From U.S. National Institutes of Health
GlaxoSmithKline Announces New Program to Provide Financial Assistance for Eligible HIV Patients in the U.S. (November 11, 2008)
If you live in the United States, use private health insurance and take Combivir (AZT/3TC), Epzicom (abacavir/3TC, Kivexa), Lexiva (fosamprenavir, Telzir) or another HIV drug made by GlaxoSmithKline, you may have a chance to save a nice chunk of change.
From GlaxoSmithKline
New Dosing Regimen for Lexiva Approved (October 12, 2007)
From U.S. Food and Drug Administration
Agenerase (Amprenavir) Oral Solution and 50-mg Capsules to Be Discontinued in the U.S. (October 2007)
To read PDF, click here
From GlaxoSmithKline
FDA Approval of Lexiva Oral Suspension and Label Changes for Pediatric Patients and Patients With Hepatic Impairment (June 18, 2007)
From U.S. Food and Drug Administration
Fosamprenavir Efficacy and Safety on Par With Other PIs, With No Gender-Based Differences (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
Pharmacokinetic Data Show That Fosamprenavir + Atazanavir Combination Should Not Be Used (February 6, 2006)
However, boosting with atazanavir instead of ritonavir does appear feasible, this study finds.
In The 13th Conference on Retroviruses and Opportunistic Infections

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.